Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
                
Learn More
Learn More
                                    PMEL17/SILV Antibody (PMEL/1825R), Novus Biologicals™
                                    
                                    
                                    
                                    
                                
                            
                            
                            
                            
Rabbit Monoclonal Antibody
Supplier: Novus Biologicals NBP253180100UG
Description
PMEL17/SILV Monoclonal specifically detects PMEL17/SILV in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin.Specifications
| PMEL17/SILV | |
| Monoclonal | |
| 0.2 mg/mL | |
| Flow Cytometry 0.5 - 1 ug/million cells, Immunocytochemistry/Immunofluorescence 0.5 - 1 ug/ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml | |
| D12S53EP1, gp100, ME20, ME20-M, melanocyte protein mel 17, Melanocyte protein Pmel 17, Melanocytes lineage-specific antigen GP100, Melanoma-associated ME20 antigen, melanosomal matrix protein17, PMEL17P100, premelanosome proteinME20M, SI, SIL, silver (mouse homolog) like, silver homolog (mouse), Silver locus protein homolog, silver, mouse, homolog of, SILVPmel17 | |
| Rabbit | |
| 95 kDa | |
| 100 μg | |
| Primary | |
| Human | |
| Purified | 
| Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin) | |
| PMEL/1825R | |
| Unconjugated | |
| 10mM PBS with 0.05% BSA with 0.05% Sodium Azide | |
| PMEL | |
| Recombinant full-length human SILV protein | |
| Protein A or G purified | |
| RUO | |
| 6490 | |
| Store at 4C. | |
| IgG κ | 
                    Product Content Correction
                
                Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
			
            For Research Use Only
Spot an opportunity for improvement?Share a Content Correction